Navigation Links
Burgeoning Population of Hepatitis C Virus Patients in Need of Second- and Third-Line Treatment Options
Date:9/5/2007

Patient Forecast Projects Significant Expansion of Drug-Treated Population, But Only For a Limited Time Due to a Cohort Effect, According to a New

Report from Decision Resources

WALTHAM, Mass., Sept. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, has found that a significant proportion of hepatitis C virus (HCV) patients do not achieve a sustained virologic response or are not able to tolerate current first-line treatment. According to the new report entitled Hepatitis C Virus Patient Flow Model and Treatment Algorithm, although currently available therapies can cure HCV, these agents are effective in only about half of all patients who receive therapy. The lack of available efficacious second- and third-line therapies leads to the accumulation of patients who are non-responsive to first-line therapy. Because HCV is not a highly fatal disease, this growing population is awaiting the launch of novel therapies and represents an important segment in the HCV market.

Hepatitis C virus represents a large commercial opportunity for drug developers due to its high prevalence, the relatively poor efficacy and side effects of current therapies and its large undiagnosed and under treated population.

"A sizeable cohort of the HCV-infected patients is aging, developing progressive liver disease, and is awaiting the introduction of several innovative new therapies in late-stage development," said John Lebbos, M.D., therapeutic area director at Decision Resources. "However, over the longer term, the size of the candidate population for treatment will be limited due to the dramatic decreases in the incidence of HCV that have been achieved as well as the improved efficacy of novel agents."

Based on this report, Decision Resources is offering an exclusive, in- depth webinar entitled Hepatitis C Virus: Forecasting the Drug-Treated and Treatment Eligible Populations from 2006 to 2021. The webinar, presented by Dr. Lebbos, will be held at 10 AM (EDT) on September 25, 2007. To register, visit http://www.DecisionResources.com.

About Hepatitis C Virus Patient Flow Model and Treatment Algorithm

This specialized report includes a detailed, annualized patient forecast model of the HCV population from 2006 to 2021 which includes the incidence- and mortality-based model includes estimates of the number of patients eligible for first-, second-, third, and fourth-line treatment by genotype and the impact of novel, more effective therapies on the epidemic and treatment- eligible populations. The HCV patient flow model also allows the user to adjust key assumptions, providing the model with flexibility to model different scenarios.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Poor health care in Russia maybe causing Decline in its Population
2. Scorecard to help in diabetic risk assessment of the Indian Population
3. Increasing risk of heart failure for ageing population
4. Prime Minister Manmohan Against Incentive-Based Population Control
5. Pigs Population A Major Threat To Encephalitis Ravaged UP
6. Scorecard to help in diabetic risk assessment of the Indian Population
7. Elderly Population’s Sedentary Lifestyle Is Dependant On Their Expectations From Lif
8. Rural Population Enjoys Better Mental Health
9. Prevention And Control Of Diabetes Crucial To Indian Population
10. World population To Be Seven billion in Six Years
11. Inclination of North Carolina’s Elderly Population towards Home Remedie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... In honor of National Physical Fitness and Sports ... who share their fitness journey on social media. , The foot care company, ... a $100 product voucher each week during May to one winner. , “Whether the ...
(Date:5/2/2016)... ... 02, 2016 , ... East Los Angeles dentist , Dr. Ramin Assili, ... Assili to receive any dental extraction treatment for $40 off the regular price. This ... With the lower price, patients can more easily afford extractions to eliminate teeth that ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Rassouli, dentist ... and cognitive decline. According to the research, which was published in the “Journal of ... cognitive decline, and about 5.4 million Americans have Alzheimer’s disease. The study found that ...
(Date:5/2/2016)... ... May 02, 2016 , ... Pregnancy Awareness Month offers a great time ... , “If you are ready to have a baby, it’s best to get ... Journal Babies is your Personal Conception & Pregnancy Organizer, written for women who plan ...
(Date:5/2/2016)... ... ... Kulbersh of Carolina Facial Plastics isn’t surprised that Charlotte, NC, the city where he and ... Cities with the Highest Plastic Rates .” The other cities that made the list ... a survey by RealSelf and combining that data with the number of board-certified ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Automation is one of the best ... growing demands for productivity in speed, accuracy, throughput and ... already adept of a wide range of functions that ... Instrumentation continues to evolve, and is poised to tackle ... years ago. Originally used mostly by the big pharmaceutical ...
(Date:4/28/2016)...  While Abbott,s announced purchase of St. Jude ... and stent business, healthcare research firm Kalorama Information ... into patient monitoring.  Kalorama said that patient monitoring ... with double-digit growth expected the next 5 years, ... Patient Monitoring . Abbott Laboratories agreed to ...
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
Breaking Medicine Technology: